Loading...

KLTO KLOTHO NEUROSCIENCES INC Company Mergers 8-K Filing

KLTH

KLT

KLOTHO NEUROSCIENCES INC

(KLTO)

2025 8-K

Summary

Summary

Subscription Agreement Update

Nasdaq Compliance Notice

Licensing Agreement

Voluntary Delisting

Pre-Market Approval

Product Expansion

Market Expansion

Asset Acquisitions

Rights Offerings

Reverse Stock Split

Nasdaq Compliance

Nasdaq Compliance Extension

Share Exchange Agreement

Delisting Notice

Capital Structure Change

Convertible Note Agreement

Board Appointment

Agreement Termination

Accountant Change

CEO Employment Agreement

Advisory Board Appointment

Director Resignation

Management Changes

Nasdaq Delisting Notice

Resignation of CFO

Business Combination and Na...

Business Combination Filing

Merger Agreement

Non-Redemption Agreement

Special Meeting of Stockhol...

Adjournment of Special Meeting

Adjournment of Special Meeting

Adjournment of Special Meeting

Adjournment of Special Meeting

Amendment and Charter Amend...

Business Combination Agreem...

Promissory Note Issued

Merger Agreement

Merger of Equals

Entry into Material Definit...

Promissory Note Issued

External Links:

On July 16, 2025, Klotho Neurosciences, Inc. entered a licensing agreement with AAVnerGene Inc. for exclusive rights to use their platform for developing gene therapies, with fees scaling up from $250,000 to $500,000 for three products and a 2% royalty on revenue.

AI Assistant

KLOTHO NEUROSCIENCES INC

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.